PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

DEMETHER is a phase II trial exploring the maintenance of trastuzumab and pertuzumab fixed dose combination (FDC) for subcutaneous administration (SC, PHESGO) following trastuzumab deruxtecan (T-DXd) as induction treatment for HER2-positive unresectable locally recurrent or metastatic breast cancer (MBC) patients.

Trial Details

NCT ID
NCT06172127
Phase
PHASE2
Sponsor
MedSIR
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Trastuzumab deruxtecan
  • Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection
  • Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • New York, New York, United States|40.71427,-74.00597
  • Marseille, France|43.29695,5.38107
  • Paris, France|48.85341,2.3488
  • Paris, France|48.85341,2.3488

Key Eligibility Criteria

  • To be eligible to participate in this trial, an individual must meet ALL the following criteria:
  • Patient must be capable to understand the purpose of the study and have signed written informed consent form (ICF) prior to beginning specific prot…
  • Male or female patients ≥ 18 years of age at the time of signing ICF.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →